Annexin Pharmaceuticals AB (publ) (ANNX.ST)
SEK 0.43
(-1.61%)
SEK 0.43
(-1.61%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -44.17 Million SEK | -8.48% |
| 2022 | -40.72 Million SEK | 20.51% |
| 2021 | -51.23 Million SEK | -17.14% |
| 2020 | -43.73 Million SEK | -54.39% |
| 2019 | -28.32 Million SEK | 1.3% |
| 2018 | -28.7 Million SEK | 6.98% |
| 2017 | -30.85 Million SEK | -215.36% |
| 2016 | -9.78 Million SEK | -94.69% |
| 2015 | -5.02 Million SEK | -262.3% |
| 2014 | -1.38 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -12.45 Million SEK | 16.36% |
| 2024 Q2 | -14.44 Million SEK | -15.96% |
| 2024 Q3 | -10.92 Million SEK | 24.35% |
| 2023 Q3 | -10.72 Million SEK | -25.02% |
| 2023 Q2 | -8.57 Million SEK | 15.09% |
| 2023 FY | -44.03 Million SEK | -8.14% |
| 2023 Q1 | -10.1 Million SEK | 0.2% |
| 2023 Q4 | -14.89 Million SEK | -38.9% |
| 2022 Q2 | -11.51 Million SEK | -21.86% |
| 2022 Q1 | -9.44 Million SEK | 32.72% |
| 2022 Q4 | -10.12 Million SEK | -4.95% |
| 2022 Q3 | -9.64 Million SEK | 16.23% |
| 2022 FY | -40.72 Million SEK | 20.51% |
| 2021 Q1 | -19.05 Million SEK | 40.72% |
| 2021 Q2 | -9.95 Million SEK | 47.75% |
| 2021 Q4 | -14.04 Million SEK | -71.71% |
| 2021 FY | -51.23 Million SEK | -17.14% |
| 2021 Q3 | -8.17 Million SEK | 17.88% |
| 2020 Q3 | -8.19 Million SEK | 29.28% |
| 2020 Q4 | -32.14 Million SEK | -292.18% |
| 2020 Q1 | -7.57 Million SEK | 26.82% |
| 2020 FY | -43.73 Million SEK | -54.39% |
| 2020 Q2 | -11.59 Million SEK | -52.98% |
| 2019 Q3 | -6.46 Million SEK | -8.1% |
| 2019 FY | -28.32 Million SEK | 1.3% |
| 2019 Q4 | -10.35 Million SEK | -60.2% |
| 2019 Q2 | -5.97 Million SEK | -7.98% |
| 2019 Q1 | -5.53 Million SEK | 23.75% |
| 2018 Q2 | -7.65 Million SEK | 14.73% |
| 2018 Q1 | -8.97 Million SEK | 5.89% |
| 2018 Q3 | -4.81 Million SEK | 37.01% |
| 2018 Q4 | -7.26 Million SEK | -50.65% |
| 2018 FY | -28.7 Million SEK | 6.98% |
| 2017 Q1 | -7.42 Million SEK | -110.13% |
| 2017 FY | -30.85 Million SEK | -215.36% |
| 2017 Q2 | -10.12 Million SEK | -36.44% |
| 2017 Q3 | -3.76 Million SEK | 62.83% |
| 2017 Q4 | -9.53 Million SEK | -153.23% |
| 2016 Q2 | -873 Thousand SEK | -42.18% |
| 2016 Q1 | -614 Thousand SEK | 0.0% |
| 2016 FY | -9.78 Million SEK | -94.69% |
| 2016 Q4 | -3.53 Million SEK | 25.82% |
| 2016 Q3 | -4.76 Million SEK | -445.59% |
| 2015 FY | -5.02 Million SEK | -262.3% |
| 2014 FY | -1.38 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 82.257% |
| Ziccum AB (publ) | -21.56 Million SEK | -104.898% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -169.349% |
| BioArctic AB (publ) | 252.64 Million SEK | 117.486% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -5127.929% |
| Mendus AB (publ) | -100.65 Million SEK | 56.109% |
| Genovis AB (publ.) | 54.22 Million SEK | 181.469% |
| Intervacc AB (publ) | -93.57 Million SEK | 52.793% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -184.786% |
| Active Biotech AB (publ) | -46.48 Million SEK | 4.965% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 345.3% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 20.284% |
| Aptahem AB (publ) | -10.1 Million SEK | -337.18% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 86.26% |
| Kancera AB (publ) | -65.04 Million SEK | 32.081% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 67.184% |
| Fluicell AB (publ) | -26.87 Million SEK | -64.351% |
| Saniona AB (publ) | -81.06 Million SEK | 45.505% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -257.093% |
| Biovica International AB (publ) | -126.07 Million SEK | 64.96% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -3.931% |
| AcouSort AB (publ) | -17.48 Million SEK | -152.622% |
| Xintela AB (publ) | -57.23 Million SEK | 22.821% |
| Abliva AB (publ) | -96.54 Million SEK | 54.245% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 86.399% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -1160.371% |
| OncoZenge AB (publ) | -15.9 Million SEK | -177.802% |
| Amniotics AB (publ) | -29.07 Million SEK | -51.949% |
| 2cureX AB (publ) | -36.36 Million SEK | -21.486% |
| CombiGene AB (publ) | -36.3 Million SEK | -21.68% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -201.749% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 88.508% |
| Camurus AB (publ) | 532.35 Million SEK | 108.298% |
| Corline Biomedical AB | -1.78 Million SEK | -2370.694% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 75.562% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -5.981% |
| I-Tech AB | 24.43 Million SEK | 280.79% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 94.397% |
| Cyxone AB (publ) | -21.66 Million SEK | -103.943% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 58.311% |
| Biosergen AB | -27.26 Million SEK | -62.025% |
| Cantargia AB (publ) | -290.01 Million SEK | 84.768% |
| NextCell Pharma AB | -43.17 Million SEK | -2.325% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 75.562% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -158.395% |
| Nanologica AB (publ) | -69.96 Million SEK | 36.858% |
| SynAct Pharma AB | -224.49 Million SEK | 80.322% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -84.418% |
| LIDDS AB (publ) | -40.67 Million SEK | -8.61% |
| Lipum AB (publ) | -37.25 Million SEK | -18.581% |
| BioInvent International AB (publ) | -369.94 Million SEK | 88.059% |
| Alzinova AB (publ) | -16.52 Million SEK | -167.377% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 82.57% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -590.979% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 61.61% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -119.355% |
| Simris Alg AB (publ) | -36.63 Million SEK | -20.584% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 69.86% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 85.769% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 60.171% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -281.947% |